Significats de mimetic peptides en anglès

Purpose of review: To determine the potential clinical utility of high-density lipoprotein- mimetic peptides.

ApoA-I and apoA-I mimetic peptides appear to have significant therapeutic potential in atherosclerosis.

These HDL mimetic peptides are much more effective in removing the oxidized phospholipids and other oxidized lipids.

These mimetic peptides improve LDL and HDL composition and function and reduce lesion formation in animal models of atherogenesis.

Small-molecule inhibitors of anti-apoptotic Bcl-2 proteins and BH3 mimetic peptides are promising anticancer agents.

Our findings also highlight the potential of developing apoE mimetic peptides as novel HCV entry inhibitors by targeting HCV-host interactions.

Whether HDL mimetic peptides will have therapeutic benefit in patients with renal failure will have to be determined in clinical studies.

Taken together, the results indicate that connexin- mimetic peptides block electrical signaling in rat mesenteric small arteries without exerting major nonjunctional effects.

In animal models and perhaps in humans, dysfunctional HDL can be improved by apoA-I mimetic peptides that bind oxidized lipids with high affinity.

This finding led to the design of short receptor dimer interface mimetic peptides that block the binding of superantigen and thus protect from death.

Following is a brief description of some of the HDL mimetic peptides that can improve HDL and the effect of the peptide on PON1 activity.

This review focuses on the preclinical and clinical findings for two types of therapies for the treatment of atherosclerosis: apoAI-containing compounds and apoAI mimetic peptides.

We have developed apoA-I mimetic peptides that are much smaller than apoA-I, and much more effective in removing the oxidized phospholipids and other oxidized lipids.

Purpose of review: Recent publications related to the potential use of apolipoprotein (apo)A-I and apoA-I mimetic peptides in the treatment of atherosclerosis are reviewed.

Our group has developed apoA-I mimetic peptides that are much smaller than apoA-I (18 amino acids long vs 243 in ApoA-I itself).